BAO PHARMA-B's stock price soared 6.67% during intraday trading on Monday, marking a significant rebound for the pharmaceutical company.

The surge follows an announcement that Board Chairman and controlling shareholder Dr. Liu Yanjun plans to increase his holdings of the company's shares through open market transactions within three months, expressing confidence in the group's prospects, growth potential, and long-term investment value. Additionally, the company intends to propose a special resolution at the upcoming Annual General Meeting to authorize directors to repurchase up to 10% of total issued H shares.

The board confirmed that the group's business operations remain normal with no material changes in its operational or financial condition. This positive movement comes after the stock experienced a sharp decline previously attributed to an expanded full-year net loss.